Innovative biopharmaceutical company Metsera ( MTSR 0.10%) has been climbing all year. It went public on Feb. 3 of this year, ...

Pfizer Ltd. share price jumped over 6% in Thursday's session as the company reported an increase in its net profit during ...

Pfizer reported a 19.4% YoY rise in Q2 net profit to ₹189 crore on stronger margins and higher revenue. Shares of the company ...

Biohaven Ltd. narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending.

Bristol Myers Squibb has a high dividend yield, is very cheap, and may have better growth prospects than it might seem at first glance. Pfizer now has a 7% yield, and may have found a solution to its ...

When Novo Nordisk CEO Mike Doustdar learned in late September that Metsera had accepted a $7.3 billion rival bid from Pfizer ...

Novo Nordisk maintains strong growth prospects, driven by obesity treatment market expansion. See why NVO stock is a strong ...

Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product ...

Eli Lilly and Novo Nordisk’s competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh. Who is winning?

Pfizer’s comeback, Newmont’s resilience, and Utz’s growth positioning make them compelling candidates for year-end gains.

Pfizer Inc's (NYSE: PFE) short interest as a percent of float has risen 8.25% since its last report. According to exchange ...